One other employee is undergoing treatment in a hospital after the incident that occurred on Monday evening, Laurus said.
The company, which specializes in anti-retroviral, hepatitis C and oncology drugs, said it has launched an investigation, without giving any other specifics about the incident.
Laurus said its other manufacturing blocks were running normally and that it did not expect any material impact on its operations.
It employs over 5,700 people at more than eight facilities including in the Indian cities of Hyderabad and Visakhapatnam, according to a July filing.
Laurus's shares fell as much as 2.4% in early trading on Tuesday, before recovering to trade down 0.5%. They had already declined about 29% so far this year.
(Reporting by Praveen Paramasivam in Chennai; Editing by Janane Venkatraman)
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)